RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation

Blood

Volumn 101, Issue 11, 2003, Pages 4333-4341

  Elagib, Kamaleldin E ^b   Racke, Frederick K ^b   Mogass, Michael ^b   Khetawat, Rina ^b   Delehanty, Lorrie L ^b   Goldfarb, Adam N ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR RUNX 1; UNCLASSIFIED DRUG; ALPHA2 INTEGRIN; DNA BINDING PROTEIN; ERYTHROID SPECIFIC DNA BINDING FACTOR; GATA1 PROTEIN, HUMAN; GLYCOPROTEIN IIB; ONCOPROTEIN; RUNX1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR RUNX1;

ARTICLE; BONE MARROW; CELL ACTIVATION; CELL CONTACT; CELL STRAIN K 562; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; EMBRYO; ENZYME ACTIVATION; ERYTHROBLAST; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKEMIA; MEGAKARYOPOIESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STROMA CELL; TRANSACTIVATION; TRANSCRIPTION REGULATION; UPREGULATION; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL LINEAGE; CHEMISTRY; CYTOLOGY; ERYTHROID PRECURSOR CELL; GENE EXPRESSION REGULATION; MEGAKARYOCYTE; METABOLISM; PHYSIOLOGY;

CELL DIFFERENTIATION; CELL LINEAGE; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA-BINDING PROTEINS; ERYTHROID PROGENITOR CELLS; ERYTHROID-SPECIFIC DNA-BINDING FACTORS; GATA1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; HUMANS; INTEGRIN ALPHA2; K562 CELLS; LEUKEMIA; MEGAKARYOCYTES; ONCOGENE PROTEINS, FUSION; PLATELET MEMBRANE GLYCOPROTEIN IIB; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION FACTORS;

EID: 0038819114     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2708     Document Type: Article

References (63)

1. Debili N, Coulombel L, Croisille L, et al. Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow. Blood. 1996; 88:1284-1296.
2. Vannucchi AM, Paoletti F, Linari S, et al. Identification and characterization of a bipotent (erythroid and megakaryocytic) cell precursor from the spleen of phenylhydrazine-treated mice. Blood. 2000;95:2559-2568.
3. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature. 2000;404: 193-197.
4. Goldfarb AN, Wong D, Racke FK. Induction of megakaryocytic differentiation in primary human erythroblasts: a physiologic basis for leukemic lineage plasticity. Am J Pathol. 2001;158:1191-1198.
5. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell. 1995;81:695-704.
6. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocytic growth and platelet development. EMBO J. 1997;16:3965-3973.
7. Tsang AP, Fujiwara Y, Hom DB, Orkin SH. Failure of megakaryopoiesis and arrested erythropoiesis in mice lacking the GATA-1 transcriptional cofactor FOG. Genes Dev. 1998;12:1176-1188.
8. Chang AN, Cantor AB, Fujiwara Y, et al. GATA-factor dependence of the multitype zinc-finger protein FOG-1 for its essential role in megakaryopoiesis. Proc Natl Acad Sci U S A. 2002;99:9237-9242.
9. Seshasayee D, Gaines P, Wojchowski DM. GATA-1 dominantly activates a program of erythroid gene expression in factor-dependent myeloid FDCW2 cells. Mol Cell Biol. 1998;18:3278-3288.
10. Visvader JE, Elefanty AG, Strasser A, Adams JM. GATA-1 but not SCL induces megakaryocytic differentiation in an early myeloid line. EMBO J. 1992;11:4557-4564.
11. Yamaguchi Y, Zon LI, Ackerman SJ, Yamamoto M, Suda T. Forced GATA-1 expression in the murine myeloid cell line M1: induction of c-Mpl expression and megakaryocytic/erythroid differentiation. Blood. 1998;91:450-457.
12. Pevny L, Simon MC, Robertson E, et al. Erythroid differentiation in chimeric mice blocked by a targeted mutation of the gene for transcription factor GATA-1. Nature. 1991;349:257-260.
13. Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood. 1999;93: 2867-2875.
14. Nichols KE, Crispino JD, Poncz M, et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA-1. Nat Genet. 2000;24:266-270.
15. Mehaffey MG, Newton AL, Gandhi MJ, Crossley M, Drachman JG. X-linked thrombocytopenia caused by a novel mutation of GATA-1. Blood. 2001;98:2681-2688.
16. Cantor AB, Katz SG, Orkin SH. Distinct domains of the GATA-1 cofactor FOG-1 differentially influence erythroid versus megakaryocytic maturation. Mol Cell Biol. 2002;22:4268-4279.
17. Tracey WD, Speck NA. Potential roles for RUNX1 and its orthologs in determining hematopoietic cell fate. Sem Cell Dev Biol. 2000;11:337-342.
18. Bushweller JH. CBF: a biophysical perspective. Sem Cell Dev Biol. 2000;11:377-382.
19. Nucifora G, Rowley JD. AML 1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood. 1995;86:1-14.
20. Lutterbach B, Hiebert SW. Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. Gene. 2000;245:223-235.
21. Song W-J, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukemia. Nat Genet. 1999;23:166-175.
22. Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99:1364-1372.
23. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148-152.
24. Visvader JE, Crossley M, Hill J, Orkin SH, Adams JM. The C-terminal zinc finger of GATA-1 or GATA-2 is sufficient to induce megakaryocytic differentiation of an early myeloid cell line. Mol Cell Biol. 1995;15:634-641.
25. Meyers S, Lenny N, Hiebert SW. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol. 1995;15: 1974-1982.
26. Britos-Bray M, Friedman AD. Core binding factor cannot synergistically activate the myeloperoxidase proximal enhancer in immature myeloid cells without c-Myb. Mol Cell Biol. 1997;17:5127-5135.
27. Tsai S-F, Martin DIK, Zon LI, D'Andrea AD, Wong GG, Orkin SH. Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells. Nature. 1989;339:446-451.
28. Racke FK, Wang D, Zaidi Z, et al. A potential role for protein kinase C-ε in regulating megakaryocytic lineage commitment. J Biol Chem. 2001; 276:522-528.
29. ARF tumor suppressor in acute myeloid leukemia. Nat Med. 2002;8:743-750.
30. Persons DA, Allay JA, Allay ER, et al. Enforced expression of the GATA-2 transcription factor blocks normal hematopoiesis. Blood. 1999;93: 488-499.
31. Goldfarb AN, Delehanty LL, Wang D, Racke FK, Hussaini IM. Stromal inhibition of megakaryocytic differentiation correlates with blockade of signaling by protein kinase C-ε and ERK/MAPK. J Biol Chem. 2001;276:29526-29530.
32. Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high-titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci U S A. 1996;93: 11400-11406.
33. Zeng C, Van Wijnen AJ, Stein JL, et al. Identification of a nuclear matrix targeting signal in the leukemia and bone-related AML/CBF-α transcription factors. Proc Natl Acad Sci U S A. 1997;94:6746-6751.
34. Huang G, Shigesada K, Ito K, Wee H-J, Yokomizo T, Ito Y. Dimerization with PEBP2β protects RUNX1/ AML1 from ubiquitin-proteasome-mediated degradation. EMBO J. 2001;20:723-733.
35. Lewis TS, Hunt JB, Aveline LD, et al. Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry. Mol Cell. 2000;6:1343-1354.
36. Racke FR, Lewandowska K, Goueli S, Goldfarb AN. Sustained activation of the extracellular signal-regulated kinase/mitogen-activated protein kinase is required for megakaryocytic differentiation of K562 cells. J Biol Chem. 1997;272:23366-23370.
37. Kundu M, Chen A, Anderson S, et al. Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11. Blood. 2002;100:2449-2456.
38. Tsang AP, Visvader JE, Turner CA, et al. FOG, a multiple zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell. 1997;90: 109-119.
39. Pulford K, Lecointe N, Leroy-Viard K, Jones M, Mathieu-Mahul D, Mason DY. Expression of TAL-1 proteins in human tissues. Blood. 1995;85: 675-684.
40. Era T, Takagi T, Takahashi T, Bories J-C, Nakano T. Characterization of hematopoietic lineage-specific gene expression by ES cell in vitro differentiation induction system. Blood. 2000;95:870-878.
41. Blobel GA, Nakajima T, Eckner R, Montminy M, Orkin SH. CREB-binding protein cooperates with the transcription factor GATA-1 and is required for erythroid differentiation. Proc Natl Acad Sci U S A. 1998;95:2061-2066.
42. Warren AJ, Colledge WH, Carlton MBL, Evans MJ, Smith AJH, Rabbitts TH. The oncogenic cysteine-rich LIM domain protein Rbtn2 is essential for erythroid development. Cell. 1994;78:45-57.
43. Elwood NJ, Zogos H, Pereira DS, Dick JE, Begley CG. Enhanced megakaryocyte and erythroid development from normal human CD34+ cells: consequences of enforced expression of SCL. Blood. 1998;91:3756-3765.
44. Saleque S, Cameron S, Orkin SH. The zinc-finger proto-oncogene Gfi-1b is essential for development of the erythroid and megakaryocytic lineages. Genes Dev. 2002;16:301-306.
45. Bastian LS, Kwiatkowski BA, Breininger J, Danners S, Roth G. Regulation of the megakaryocytic glycoprotein IX promoter by the oncogenic ets transcription factor Fli-1. Blood. 1999;93:2637-2644.
46. Hart A, Melet F, Grossfeld P, et al. Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity. 2000;13:167-177.
47. Spyropoulos DD, Pharr PN, Lavenburg KR, et al. Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol Cell Biol. 2000;20:5643-5652.
48. Fong AM, Santoro SA. Transcriptional regulation of αIIb integrin gene expression during megakaryccytic differentiation of K562 cells. J Biol Chem. 1994; 269:18441-18447.
49. Villa-Garcia M, Li L, Riely G, Bray PF. Isolation and characterization of a TATA-less promoter for the human β3 integrin gene. Blood. 1994;83:668-676.
50. Zutter MM, Painter AA, Staatz WD, Tsung YL. Regulation of alpha 2 integrin gene expression in cells with megakaryocytic features: a common theme of three necessary elements. Blood. 1995; 86:3006-3014.
51. Deveaux S, Filipe A, Lemarchandel V, Ghysdael J, Romeo P-H, Mignotte V. Analysis of the thrombopoietin receptor (mpl) promoter implicates GATA and Ets proteins in the ceregulation of megakaryocyte-specific genes. Blood. 1996;87: 4678-4685.
52. Zhang C, Gadue P, Scott E, Atchison M, Poncz M. Activation of the megakaryocyte-specific gene platelet basic protein (PBP) by the Ets family factor PU.1. J Biol Chem. 1997;272:26236-26246.
53. Deveaux S, Cohen-Kaminsky S, Shivdasani RA, et al. p45 NF-E2 regulates expression of thromboxane synthase in megakaryocytes. EMBO J. 1997;16:5654-5661.
54. Kim W-Y, Sleweke M, Ogawa E, et al. Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. EMBO J. 1999;18:1609-1620.
55. Gu T-L, Goetz TL, Graves BJ, Speck NA. Autoinhibition and partner proteins, core-binding factor β (CBFβ) and Ets-1, modulate DNA binding by CBFα2 (AML1). Mol Cell Biol. 2000;20:91-103.
56. Cai Z, de Bruijn M, Ma X, et al. Haploinsufficiency of AML1 affects the temporal and spatial generation of hematopoietic stem cells in the mouse embryo. Immunity. 2000;13:423-431.
57. Shivdasani RA. Molecular and transcriptional regulation of megakaryocyte differentiation. Stem Cells. 2001;19:397-407.
58. Ichikawa M, Asai T, Saito T, et al. AML1 is required for megakaryocytic maturation in adult hematopoiesis [abstract]. Blood. 2002;100:130-131.
59. Lebestky T, Chang T, Hartenstein V, Banerjee U. Specification of Drosophila hematopoietic lineage by conserved transcription factors. Science. 2000;288:146-149.
60. Brunning RD, McKenna RW. Acute myeloid leukemias: tumors of the bone marrow. In: Atlas of Tumor Pathology. Ed 1. Vol 9. Washington, DC: Armed Forces Institute of Pathology; 1994: 22-100.
61. Kalev-Zylinska ML, Horsfield JA, Flores MVC, et al. Runx1 is required for zebrafish blood and vessel development and expression of a human RUNX1-CBF2T1 transgene advances a model for studies of leukemogenesis. Development. 2002;129:2015-2030.
62. Tracey WD, Pepling ME, Horb ME, Thomsen GH, Gergen JP. A Xenopus homologue of aml-1 reveals unexpected patterning mechanisms leading to the formation of embryonic blood. Development. 1998;125:1371-1380.
63. Tonks A, Pearn L, Tonks AJ, et al. The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood. 2003;101: 624-632.